Sen-Jam Pharmaceutical Positions SJP-002C as a Transformative Complement to GLP-1 Therapies and a Standalone Solution for MASH
HUNTINGTON, N.Y., Aug. 12, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical today announced significant progress in advancing its innovative immuno-regulator platform aimed…
